- Open Access
Dexamethasone inhibits IL-9 production by human T cells
Journal of Inflammation volume 2, Article number: 3 (2005)
Interleukin 9 (IL-9) is produced by activated CD4+ T cells. Its effects include stimulation of mucus production, enhanced mast cell proliferation, enhanced eosinophil function, and IgE production. These effects are consistent with a role in allergic diseases. Glucocorticoids have potent anti-inflammatory effects, including suppression of cytokine synthesis, and are widely used in the treatment of allergic conditions.
We examined the effect of the glucocorticoid dexamethasone (Dex) on IL-9 mRNA expression and protein secretion with real-time RT-PCR and ELISA. Peripheral blood mononuclear cells (PBMC) were prepared from human volunteers and activated with OKT3. CD4+ T cells were purified from PBMC and activated with OKT3 plus PMA.
IL-9 mRNA abundance and protein secretion were both markedly reduced following treatment of activated PBMC with Dex. mRNA levels were reduced to 0.7% of control values and protein secretion was reduced to 2.8% of controls. In CD4+ T cells, Dex reduced protein secretion to a similar extent. The IC50 value of Dex on mRNA expression was 4 nM.
These results indicate that IL-9 production is very markedly inhibited by Dex. The findings raise the possibility that the beneficial effects of glucocorticoids in the treatment of allergic diseases are in part mediated by inhibition of IL-9 production.
CD4+ T cells of the T helper 2 (Th2) type have been implicated as major contributors to the pathology of allergic asthma . Th2 cells produce the cytokines IL-4, IL-5, IL-9 and IL-13. IL-9, which was first identified as a T cell growth factor , has multiple effects consistent with a role in allergic inflammation. IL-9 acts on the pulmonary epithelium to induce production of mucus  and chemokines . It enhances eosinophil function via induction of the IL-5 receptor . IL-9 induces immunoglobulin synthesis of all isotypes, especially IgE . Mast cell numbers are elevated in the lung by IL-9 .
There is evidence in clinical studies for an association between IL-9 and allergic asthma. In bronchial biopsies, the cells expressing IL-9, which were predominantly T cells, were increased in patients with allergic asthma, and this was associated with bronchial hyper-reactivity [8, 9]. An association between IL-9 expressing cells and eosinophilia has also been described . In allergic asthma patients, IL-9 in the bronchoalveolar fluid was increased after segmental allergen challenge . Among a range of cytokines produced by in vitro stimulated PBMC, IL-9 was found to have the best correlation with allergic reactivity as measured by skin prick tests .
Several animal studies have investigated the role of IL-9 in allergic asthma. In transgenic mice with elevated pulmonary expression of IL-9, there was increased influx of inflammatory cells to the lungs, increased mucus production and increased mast cell numbers . In two separate mouse model studies of allergen-induced asthma, administration of neutralising anti-IL-9 antibodies reduced eosinophilia, BHR, airway damage and IgE [14, 15]. In a model of parasitic infection with a Th2 response, IL-9 knockout mice displayed markedly reduced goblet cell hyperplasia and mastocytosis . However, in a model of allergic asthma, airway hyperreactivity, eosinophilia and goblet cell hyperplasia were not impaired in IL-9 knock-out mice . Despite the findings in knock-out mice, overall the evidence from animal models is consistent with clinical evidence that IL-9 may have a role in allergic asthma.
Glucocorticoids (GC) are a major component of the treatment of asthma and other allergic disorders. GC bind to cytoplasmic glucocorticoid receptors (GR) and GC/GR complexes translocate to the cell nucleus where they stimulate or inhibit the transcription of a large number of genes. The anti-inflammatory effects of GC have been associated with inhibition of transcription of numerous cytokines . GC markedly reduce gene transcription of the Th2 cytokines IL-4 , IL-5  and IL-13  as well as inhibiting the production of many other cytokines including IL-2 , GM-CSF  and interferon gamma (IFN-γ) . By contrast, GC induce the expression of certain cytokines, including IL-10 , IL-1 receptor antagonist (IL-1Ra)  and transforming growth factor-beta , and GC do not affect expression of M-CSF .
Given the extensive evidence indicating IL-9 may be a candidate cytokine in the pathogenesis of allergic diseases, further research into the regulation of IL-9 production is warranted. Because glucocorticoids are effective in the treatment of allergic diseases, it is important to understand their effects on genes that are potentially relevant to the pathogenesis of these diseases. Therefore we have investigated the effect of the synthetic glucocorticoid dexamethasone (Dex) on IL-9 production.
Peripheral blood was donated by healthy volunteers from the Garvan Institute of Medical Research and the Centre for Immunology. The procedures were approved by the Human Research Ethics Committee, St Vincent's Hospital, Sydney and are in compliance with the Helsinki Declaration. Peripheral blood mononuclear cells (PBMC) were isolated by ficoll-based density centrifugation. Cells were resuspended in complete medium consisting of RPMI 1640 medium (JRH Biosciences, Lenexa, KS, USA) supplemented with 10% v/v heat-inactivated foetal bovine serum (FBS) (CSL Ltd, Parkville, Australia), 2 mM L-glutamine, 20 mM HEPES buffer, 100 U/mL penicillin and 100 μg/mL streptomycin (all from Invitrogen, Carlsbad, CA, USA). Cell counts and viabilities were determined by trypan blue exclusion in a haemocytometer. Viability was always greater than 95%.
PBMC were adjusted to 1 × 106 cells/mL and were incubated at 37°C in 5% CO2 for the activation period. PBMC were treated with 100 ng/mL OKT3 (diluted in PBS) or with a corresponding volume of PBS. OKT3, a kind gift of Janssen-Cilag, Sydney, Australia, causes T cell activation by binding to the T-cell specific surface molecule CD3. Cells were treated with Dex (Sigma, Castle Hill, Australia) or with a corresponding volume of PBS. Dex was diluted in PBS and added immediately after OKT3.
In some experiments, CD4+ T cells were purified by incubating PBMC in complete medium for 90 minutes at 37°C and 5% CO2 to deplete adherent cells. The non-adherent cells were then centrifuged and resuspended in MACS Buffer (0.5% FBS and 2 mM EDTA in PBS) and MACS human CD4+ micro beads (Miltenyi Biotec, Auburn, California, USA) according to the manufacturer's instructions. After incubation, the cells were washed and CD4+ cells were then isolated by a MACS LS Column placed in a MACS Separator according to the manufacturer's instructions (Miltenyi).
Small aliquots of the CD4+ cells were analysed by flow cytometry. Cells were stained with anti-CD3 FITC and anti-CD4 PE antibodies and analysed on a FACSCalibur using CellQuest software (all BD Biosciences, San Jose, CA). At least 98% of the cells expressed CD3 and CD4. CD4+ cells were cultured as above except that they were stimulated with a combination of 8 ng/mL PMA (Sigma) and plate-bound OKT3. OKT3 was bound to 12-well plates by addition of 10 μg/mL of OKT3 in PBS at 4°C overnight. The antibody solution was removed immediately prior to addition of the cells.
After culture for 24 hours, cells were centrifuged at 440 g for 5 min. Total RNA was extracted by Trizol (Invitrogen) according to the manufacturer's instructions. RNA was dissolved in DEPC-treated water and stored at -70°C until required. RNA concentration was determined by spectrophotometry. 2 μg of total RNA was heated to 65°C for 5 min, cooled for 2–3 min on ice, and reverse transcribed by avian myeloblastosis virus reverse transcriptase (AMV-RT), with 1 μM oligo (dT)15 primer (Roche, Castle Hill, Australia), 20U AMV-RT enzyme (Roche), 1 mM dNTP (Roche), AMV-RT buffer (50 mM Tris-HCl, 8 mM MgCl2, 30 mM KCl, 1 mM dithiothreitol) (Roche) and DEPC-water in a 20 μL volume at 42°C for 1 hour. Tubes were heated to 65°C for 5 min and stored at -20°C until required.
For IL-9 PCR, in a 20 μL reaction mixture, 1 μL cDNA was amplified by Platinum Quantitative PCR Supermix UDG (1.5 U Platinum Taq Polymerase, 20 mM Tris-HCl, 50 mM KCl, 3 mM MgCl2, 200 μM dGTP, 200 μM dATP, 200 μM dCTP, 200 μM dUTP, 1U Uracil DNA glycosylase (UDG)) (Invitrogen), Milli-Q water, 0.4 μM of the forward and reverse primers and Taqman probe (Geneworks, Rundle Mall, Adelaide, Australia) with sequences 5'CCTGGACATCAACTTCCTCATC3', 5'CATGGCTGTTCACAGGAAAA3' and 5'FAM-CTCTGACAACTGCACCAGA-TAMRA3', respectively. PCR was performed with a Rotorgene 3000 real-time PCR machine (Corbett Research, Mortlake, Sydney, Australia). No template controls (NTC) with water instead of cDNA were included in all experiments. The reaction conditions for the IL-9 real-time PCR were 95°C for 3 min followed by 40 cycles of 95°C for 15 sec then 60°C for 60 sec. Forward and reverse primers were designed to bind to different exons so that any genomic DNA amplification could be distinguished from cDNA.
The PCR amplification efficiency was determined in every experiment by serial four-fold dilutions of the activated sample containing no Dex. These diluted samples and all the undiluted samples were analysed again in duplicate by real-time PCR under the same conditions. The amplification efficiency was determined by plotting the mean threshold cycle (Ct) value of the diluted samples against the log of the dilution. IL-9 amplification efficiencies ranged from 1.63 to 1.99. The actual amplification efficiencies were then used to determine the ratios of samples treated with and without Dex.
A β-actin PCR was also performed on each sample. 1 μL cDNA was amplified in 25 μL in PCR buffer (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl) (Roche), 0.25 mM dNTP (Roche), 1 X SybGr (Molecular Probes, Eugene, OR, USA), 0.75 U Taq polymerase (Roche), 2 mM MgCl2 and 0.32 μM of forward and reverse β-actin primer (Geneworks) with sequences 5'CCAACTGGGACGACATG3' and 5'CAGGGATAGCACAGCCT3' respectively . Samples were amplified by 94°C for 2 min followed by 30 cycles of 94°C for 15 sec, 56°C for 20 sec and 72°C for 20 sec. To confirm the identity of PCR products, all products were size-fractionated by agarose gel electrophoresis, and products with apparent mobility consistent with the expected size (277 bp for IL-9 and 203 bp for β-actin) were detected.
ELISA assays were used to determine the IL-4, IL-9 and IFN-γ concentration in the culture supernatants. The IL-9 reagents (capture antibody, standard, and detection antibody) have been described previously , whereas the IL-4 and IFN-γ kits were purchased from BD Biosciences. 384 well flat bottom MAXISorp plates (Nunc, Roskilde, Denmark) were used. In the IL-9 ELISA the capture antibody, mh9a4, was diluted in a coating buffer (20 mM glycine, 30 mM NaCl, pH 9.2) at a concentration of 5 μg/mL. After overnight incubation at 4°C and washing with 0.05% Tween-20 in PBS, the plate was blocked with the assay diluent, 1% (w/v) BSA in PBS, incubated at 37°C for at least 2 hours and washed again. Before a final overnight incubation at 4°C the samples and standards were prepared in assay diluent, and loaded into the wells in triplicate. The standards were prepared in two-fold dilutions from 500 pg/mL to 3.9 pg/mL. After washing, detection antibody mh9a3-biotin was added in a 1:2000 dilution for 2 hours at 37°C. The plates were washed and streptavidin-horseradish peroxidase conjugate was added (DakoCytomation, Glostrup, Denmark) 1:500 in assay diluent, and plates were incubated at room temperature for 30 min. The IL-4 and IFN-γ ELISA assays were performed according to the manufacturer's instructions. The lower limits of detection were 3.9–15.6 pg/mL for IL-9, 7.8 pg/mL for IL-4 and 3.9 pg/mL for IFN-γ. When results with and without Dex were presented as percentages, if a sample was undetectable in the ELISA, the lower limit of detection of the assay was used in the calculation.
All assays were washed, loaded with TMB Substrate solution (BD Biosciences) in a 1:1 mixture of TMB substrate A and B, and incubated at room temperature in the dark for 30–45 minutes before the reaction was stopped with 2 M H2SO4. Absorbance was measured by a Spectra Image reader using X-read Plus software (both Tecan, Maennedorf, Switzerland).
Samples were compared with the Wilcoxon signed rank test (Statview Software 5.0, Abacus Concepts, Berkeley, California, USA). A p value of <0.05 was considered significant.
Dexamethasone reduces IL-9 mRNA abundance
In preliminary experiments, real-time RT-PCR revealed that OKT3 was a highly effective stimulus of IL-9 expression in PBMC, as previously reported . IL-9 mRNA was induced from 4 to 48 h after activation (Fig. 1A), and 24 h was chosen as a suitable time for detection of mRNA in subsequent experiments. The effect of Dex on IL-9 mRNA abundance in PBMC was examined in 13 healthy individuals by real-time RT-PCR. PBMC were cultured with OKT3, with or without 10-6 M Dex. In all samples treated with OKT3 without Dex, IL-9 mRNA expression was readily detected. Addition of Dex to cultures stimulated by OKT3 was followed by a marked reduction in IL-9 mRNA abundance. All samples treated with Dex had much higher Ct values than those without Dex (Table 1). Statistical analysis revealed a highly significant effect of Dex (p < 0.01). All RT-PCR products were subjected to gel electrophoresis and the results were consistent with the real-time data. In the samples activated with OKT3, a single strong band was detected with apparent mobility consistent with the predicted fragment size of 277 bp (Fig. 1B). After treatment with OKT3 and Dex, a very faint band of the same mobility was detected, and no bands were detected in the unactivated samples. Except for some very low molecular size material, there was no evidence of any other band apart from the 277 bp band. The cDNA samples were also assessed for the housekeeping gene β-actin by real-time RT-PCR, and Dex had no significant effect. In activated cells, Ct values for β-actin were 15.5 ± 2.7 (SD) for samples given Dex, compared with 16.5 ± 4.6 for samples not given Dex. The findings with β-actin indicate that Dex did not cause a generalized reduction of gene expression.
The relative change in IL-9 mRNA expression produced by Dex was ascertained by calculating the difference in Ct values between the activated and activated + Dex samples (Table 1). This difference was then corrected for the amplification efficiency of samples from each individual PBMC donor. Amplification efficiency was determined by serial dilution of each of the samples activated and not treated with Dex. The percentage of IL-9 transcription in the Dex-treated samples compared to controls ranged from 0.03% to 3.57% with a mean of 0.67% and a median of 0.20%.
The effectiveness of Dex was assessed by comparing IL-9 transcription in samples not treated with Dex to samples treated with 10-6 M to 10-11M Dex. Mean Ct values of duplicate samples were determined, and in each individual the mean Ct value of the sample not treated with Dex was given a figure of 100%. PCR was then performed on serial dilutions of the samples not treated with Dex to correct for amplification efficiency as described in the Methods. Dex inhibited IL-9 transcription in PBMC activated with OKT3 in a concentration dependent manner in four different individuals. The average percentage value for each Dex concentration is plotted in Figure 2. 10-7M Dex was almost as inhibitory as 10-6 M Dex, and 10-8 M Dex reduced IL-9 transcript abundance to 20% of control levels. At lower concentrations of Dex, transcription increased towards control levels. In 2 of 4 experiments, the samples treated with 10-10 M Dex had a higher level of transcription than control samples, contributing to the slightly higher average IL-9 expression level at 10-10 M Dex compared with no Dex (Fig. 2). The concentration of Dex that inhibited 50% of IL-9 transcription in activated PBMC, the IC50, was calculated to be 10-8.4 M or 4 nM.
Dex inhibits IL-9 protein secretion
After activation with OKT3, IL-9 secretion was readily detected by sandwich ELISA. Supernatants were harvested at various times after activation, and IL-9 was measured in triplicate. The amount of IL-9 after 72 h of culture was defined as 100%. IL-9 was not detected at 0 h. At 24 h, the IL-9 level was 16 ± 1 % (mean ± SD) and at 48 h it was 85 ± 3 %. Thus IL-9 levels had almost peaked by 48 h, and supernatants were harvested at this time in subsequent experiments. PBMC from 11 different donors were treated with or without OKT3 and with or without 10-6 M Dex throughout the culture period. In all samples stimulated with OKT3, there were high levels of IL-9 secretion in the absence of Dex, and IL-9 concentrations were in the range of 207–2,526 pg/mL. IL-9 secretion was very markedly reduced after treatment with Dex (p < 0.005). In the Dex-treated samples, secretion was only 2.8 % ± 2.5% (SD) of control values (Fig. 3). In 8 of the 11 samples treated with OKT3 and Dex, the IL-9 concentration was below the lower limit of detection of the assay. In most of the cultures not treated with OKT3, IL-9 could not be detected. It was detected at very low levels in 3 samples in the absence of Dex and in 1 sample in the presence of Dex.
In six of the 11 samples, the culture supernatants were also tested for IFN-γ and IL-4. In activated cells treated with Dex, the IFN-γ and IL-4 concentrations were always above the lower detection limit of the assays. Dex significantly reduced the concentrations of both cytokines (p < 0.05 in both cases). The effect of Dex on IFN-γ secretion was similar to that on IL-9. Activated cells treated with Dex secreted 2.4 ± 2.1 % as much IFN-γ as control activated cells. By contrast, Dex had substantially less inhibitory effect on IL-4 secretion. The Dex-treated cells secreted 31.4 ± 14.1 (SD) % as much IL-4 compared with control activated cells.
CD4+ T cells were purified from 7 individuals, to determine whether Dex was acting directly on these cells. In cells not activated with OKT3, IL-9 was detected at very low levels in 4 samples without Dex and in 2 samples in the presence of Dex. Activated cells not treated with Dex secreted IL-9 in the range 222–1,939 pg/mL. As with PBMC, Dex markedly inhibited IL-9 secretion in activated cells (Fig. 4) (p < 0.02). Samples treated with 10-6 M Dex secreted only 2.9 % ± 2.5% (SD) as much IL-9 as control samples. In activated cells treated with Dex, IL-9 was below the detection limit of the assay in 3 of 7 cultures in these experiments.
The study demonstrates that Dex is an efficient pharmaceutical agent for inhibition of IL-9 production. In activated PBMC, Dex reduced IL-9 secretion to a mean of 2.8% of control levels, whereas in the case of mRNA, the corresponding value was 0.7 %. The difference between these 2 percentage values may have arisen because in the real-time PCR analysis, it was always possible to determine a value for IL-9 mRNA in the Dex-treated samples, whereas in the ELISA assay, the corresponding samples were usually undetectable. In the latter samples, the lower limit of detection of the assay was used to calculate percentages, which may have over-estimated the IL-9 concentration in the Dex-treated samples.
To determine if the inhibitory effect was specific for helper T cells, experiments were also carried out with purified CD4+ cells. These populations contained at least 98% CD3+CD4+ cells, making it very likely that the observed effects directly involve helper T cells. The data indicate that CD4+ T cells produce substantial amounts of IL-9, although the possibility that other cells in PBMC also produce IL-9 has not been excluded. Dex markedly reduced IL-9 secretion in CD4+ T cells, and the data are most consistent with a direct effect of Dex on CD4+ T cells.
Dex was found to inhibit the synthesis of IL-9 mRNA in PBMC in a concentration dependent manner. Marked inhibition of IL-9 transcription was observed with Dex concentrations as low as 10-8 M, and Dex had an IC50 value of 4 nM. Similar Dex concentration response curves have been observed with IL-2  and IL-5  expression in T cells, as well as IL-4 and IL-5 in mast cells . ICAM-1 expression  as well as prostaglandin synthesis and release in alveolar tissue  have also been found to have similar responses to a range of concentrations of Dex. IC50 values for Dex have been obtained for ICAM-1 expression of <1 nM , COX activity of 1–10 nM , IL-11 expression of 1 nM  and IL-5 expression in T cells of 1 nM . In mast cells, Dex had an IC50 value of 1.6 nM on IL-5 expression indicating that the sensitivity of T cells and mast cells to Dex is similar for Th2 cytokines . These findings, taken together, suggest that Dex may be inhibiting similar pathways involved in regulation of expression of a variety of different genes in T cells and mast cells.
Glucocorticoids can mediate effects on transcription in two ways. After translocation of the GC/GR to the nucleus, the GR can bind directly to glucocorticoid response element (GRE) sequences in the promoter regions of target genes. The expression of many genes is stimulated in this fashion. However there is limited evidence for GRE involved in inhibition of gene expression. Alternatively, GC act indirectly by GR binding to transcription factors so as to prevent them from interacting with DNA. Previous studies have found that the two mechanisms are mediated by different concentrations of Dex. The inhibitory effect of Dex on collagenase expression was found to be mediated by interaction between GC/GR and the transcription factor AP-1 . In the absence of GC, AP-1 binds to the promoter of the collagenase gene to stimulate transcription, whereas in the presence of GC, binding between GC/GR and AP-1 prevents the latter from associating with DNA, so that transcription is inhibited. Half maximal repression of collagenase expression was reached with 1.5 nM Dex, whereas half-maximal induction of gene expression via GRE binding required 10 nM or greater . We found Dex to have an IC50 value of 4 nM, consistent with an indirect effect via interference with transcription factor(s).
Among possible transcription factors, NF-AT is a likely candidate. In the case of the IL-5 promoter, we observed that Dex inhibited binding to the NF-AT site but not to the GATA-3 site . The IL-9 promoter contains binding sequences for NF-AT , and the transcription of other cytokines including IL-2  and IL-4  involves NF-AT. IL-4, IL-5 and IL-9 all reside within the Th2 gene cluster on human chromosome 5  raising the possibility that they may have similar regulatory mechanisms. Other factors which may be involved include AP-1, NF-κB and CREB, which have DNA binding sites in the IL-9 promoter  and which can be inhibited by glucocorticoids [36, 39, 40].
Expression of IL-9 by T cells may depend on the effects of other cytokines produced after activation . This is consistent with the delayed induction of IL-9 mRNA, which did not peak until 24 h after activation (Fig. 1A). It is therefore possible that the effect of Dex on IL-9 production may be a consequence of its inhibitory effect on cytokines produced earlier after T cell activation. Dex inhibited the production of the key Th1 cytokine IFN-γ to a similar extent to IL-9 (Table 2). In other experiments on PBMC, we observed that 10-6 M Dex reduced the secretion of IL-5 to 0.8 % of control PHA activated cells, and that of IL-13 to 6.2 % of controls (n = 6 for IL-5 and IL-13) (M. Irvine & W. A. Sewell, unpublished observations). However, not all Th2 cytokines are as markedly inhibited by Dex, because IL-4 was only inhibited to 31% of control levels (Table 2). The relative resistance of IL-4 to the inhibitory effects of Dex may explain an unexpected effect of Dex in enhancing the development of Th2 cells ; these findings could be explained by more efficient suppression by Dex of IFN-γ than IL-4, leaving sufficient IL-4 to favour differentiation of T cells into Th2 cells.
IL-9 mRNA expression and protein secretion were very markedly inhibited by Dex. The findings suggest that the beneficial effects of glucocorticoids in the treatment of allergic diseases may, in part, be mediated by inhibition of IL-9 production. Glucocorticoids are a mainstay in the treatment of allergic asthma and other allergic diseases, but their usefulness is limited by side effects. Drugs that inhibit effector cytokines, but lack the side effects of glucocorticoids, would potentially be very useful in the treatment of allergy. Our findings suggest that, when such novel drugs are evaluated, their effects on IL-9 should be taken into consideration.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992, 326: 298-304.
Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J: Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol. 1990, 144: 4235-4241.
Longphre M, Li D, Gallup M, Drori E, Ordonez CL, Redman T, Wenzel S, Bice DE, Fahy JV, Basbaum C: Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest. 1999, 104: 1375-1382.
Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, Haczku A, Huaux F, Arras M, Holroyd KJ, Renauld JC, Levitt RC, Nicolaides NC: IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol. 1999, 29: 2130-2139. 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S.
Gounni AS, Gregory B, Nutku E, Aris F, Latifa K, Minshall E, North J, Tavernier J, Levit R, Nicolaides N, Robinson D, Hamid Q: Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood. 2000, 96: 2163-2171.
Dugas B, Renauld JC, Pene J, Bonnefoy JY, Peti-Frere C, Braquet P, Bousquet J, Van Snick J, Mencia-Huerta JM: Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol. 1993, 23: 1687-1692.
Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R, Renauld JC: Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol. 1998, 160: 3989-3996.
Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, Wallaert B, Hamid QA: IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000, 105: 108-115. 10.1016/S0091-6749(00)90185-4.
Tsicopoulos A, Shimbara A, de Nadai P, Aldewachi O, Lamblin C, Lassalle P, Walls AF, Senechal S, Levitt RC, Darras J, Hamid Q, Wallaert B: Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. J Allergy Clin Immunol. 2004, 113: 462-469. 10.1016/j.jaci.2003.12.009.
Ying S, Meng Q, Kay AB, Robinson DS: Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: relationships to eosinophils, mast cells and T lymphocytes. Clin Exp Allergy. 2002, 32: 866-871. 10.1046/j.1365-2222.2002.01376.x.
Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, Krug N: Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol. 2003, 111: 1319-1327. 10.1067/mai.2003.1485.
Macaubas C, Sly PD, Burton P, Tiller K, Yabuhara A, Holt BJ, Smallacombe TB, Kendall G, Jenmalm MC, Holt PG: Regulation of T-helper cell responses to inhalant allergen during early childhood. Clin Exp Allergy. 1999, 29: 1223-1231. 10.1046/j.1365-2222.1999.00654.x.
Temann UA, Ray P, Flavell RA: Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest. 2002, 109: 29-39. 10.1172/JCI200213696.
Kung TT, Luo B, Crawley Y, Garlisi CG, Devito K, Minnicozzi M, Egan RW, Kreutner W, Chapman RW: Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol. 2001, 25: 600-605.
Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, Fukushima F, Ishii Y, Fukuda T: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002, 166: 409-416. 10.1164/rccm.2105079.
Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin HE, McKenzie AN: IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity. 2000, 13: 573-583. 10.1016/S1074-7613(00)00056-X.
McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM: The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med. 2002, 195: 51-57. 10.1084/jem.20011732.
Umland SP, Schleimer RP, Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 2002, 15: 35-50. 10.1006/pupt.2001.0312.
Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB: Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am Rev Respir Dis. 1993, 148: 401-406.
Rolfe FG, Hughes JM, Armour CL, Sewell WA: Inhibition of interleukin-5 gene expression by dexamethasone. Immunology. 1992, 77: 494-499.
Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, Hamid Q: Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med. 1997, 155: 845-851.
Boumpas DT, Anastassiou ED, Older SA, Tsokos GC, Nelson DL, Balow JE: Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest. 1991, 87: 1739-1747.
Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF: Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood. 1992, 79: 45-51.
Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, Billah MM: The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol. 1997, 100: 511-519.
John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, Barnes PJ, Chung KF: Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med. 1998, 157: 256-262.
Levine SJ, Benfield T, Shelhamer JH: Corticosteroids induce intracellular interleukin-1 receptor antagonist type I expression by a human airway epithelial cell line. Am J Respir Cell Mol Biol. 1996, 15: 245-251.
Batuman OA, Ferrero A, Cupp C, Jimenez SA, Khalili K: Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J Immunol. 1995, 155: 4397-4405.
Jenmalm MC, Van Snick J, Cormont F, Salman B: Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin Exp Allergy. 2001, 31: 1528-1535. 10.1046/j.1365-2222.2001.01190.x.
Sewell WA, Scurr LL, Orphanides H, Kinder S, Ludowyke RI: Induction of interleukin-4 and interleukin-5 expression in mast cells is inhibited by glucocorticoids. Clin Diagn Lab Immunol. 1998, 5: 18-23.
Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G: A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992, 89: 9991-9995.
Newton R, Seybold J, Kuitert LM, Bergmann M, Barnes PJ: Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem. 1998, 273: 32312-32321. 10.1074/jbc.273.48.32312.
Wang J, Zhu Z, Nolfo R, Elias JA: Dexamethasone regulation of lung epithelial cell and fibroblast interleukin-11 production. Am J Physiol. 1999, 276: L175-185.
Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P: Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990, 62: 1189-1204. 10.1016/0092-8674(90)90395-U.
Quan A, McCall MN, Sewell WA: Dexamethasone inhibits the binding of nuclear factors to the IL-5 promoter in human CD4 T cells. J Allergy Clin Immunol. 2001, 108: 340-348. 10.1067/mai.2001.118512.
Zhu YX, Kang LY, Luo W, Li CC, Yang L, Yang YC: Multiple transcription factors are required for activation of human interleukin 9 gene in T cells. J Biol Chem. 1996, 271: 15815-15822. 10.1074/jbc.271.26.15815.
Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT: Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest. 1993, 91: 1481-1489.
Chen R, Burke TF, Cumberland JE, Brummet M, Beck LA, Casolaro V, Georas SN: Glucocorticoids inhibit calcium- and calcineurin-dependent activation of the human IL-4 promoter. J Immunol. 2000, 164: 825-832.
Renauld JC: New insights into the role of cytokines in asthma. J Clin Pathol. 2001, 54: 577-589. 10.1136/jcp.54.8.577.
Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994, 91: 752-756.
Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK: Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol Chem. 1993, 268: 5353-5356.
Houssiau FA, Schandene L, Stevens M, Cambiaso C, Goldman M, van Snick J, Renauld JC: A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. J Immunol. 1995, 154: 2624-2630.
Ramirez F: Glucocorticoids induce a Th2 response in vitro. Dev Immunol. 1998, 6: 233-243.
The work was supported by a grant from the St Vincent's Hospital Research Committee.
The author(s) declare that they have no competing interests.
LEH performed the RT-PCR experiments. KPJ performed the ELISA experiments. LEH and KPJ drafted the manuscript. JvS prepared the anti-IL-9 antibodies and revised the manuscript. FC prepared the anti-IL-9 antibodies. WAS conceived of the project, supervised its design and coordination, and revised the manuscript. All authors read and approved the final manuscript.
Lauren E Holz, Kristoffer P Jakobsen contributed equally to this work.
About this article
Cite this article
Holz, L.E., Jakobsen, K.P., Van Snick, J. et al. Dexamethasone inhibits IL-9 production by human T cells. J Inflamm 2, 3 (2005). https://doi.org/10.1186/1476-9255-2-3
- Peripheral Blood Mononuclear Cell
- Allergic Asthma
- Goblet Cell Hyperplasia
- Glucocorticoid Response Element
- Mast Cell Number